Vancouver, British Columbia — December 24, 2025 — Leads & Copy — Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) has released its financial results for the fiscal year ended August 31, 2025, reporting revenues of $5.8 million and an Adjusted EBITDA loss of $402K. The company is strategically reinvesting revenues to enhance R&D and commercialization capacity, leading to significant accomplishments.
According to the release, Telescope Innovations continues to achieve technical milestones for its multi-year, funded project with Pfizer for Self-Driving Lab (SDL) development. The company is also pursuing new commercialization opportunities for SDLs in Asia, with the first SDL for pharmaceutical development in Korea scheduled for deployment in FY 26.
Telescope Innovations reports the strongest sales performance quarters to date for DirectInject-LC™, with expansion in Europe and a launch in Asia. Additionally, the company has produced battery-grade lithium sulfide through its proprietary low-temperature method and shipped initial samples to battery industry groups in North America and Asia.
Financial highlights for the fiscal year ended August 31, 2025, include revenues of $5.8 million, compared to $4.4 million for FY 2024. Expenses totaled $7.3 million, versus $5.8 million for FY 2024. The Adjusted EBITDA loss was $402,000, compared to a loss of $152,000 for FY 2024. All values are represented in CAD.
CEO Henry Dubina stated that these results reflect the growing validation of Telescope’s technology across multiple end markets. He noted the progress on the SDL program with Pfizer, record DirectInject-LC™ sales, and the delivery of battery-grade lithium sulfide, marking FY 2025 as an important transition from development to commercialization.
Telescope Innovations is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The company builds and deploys new enabling technologies, including flexible robotic platforms and artificial intelligence software, to improve experimental throughput, efficiency, and data quality. The company aims to bring modern chemical technology solutions to meet the most serious challenges in health and sustainability.
Henry Dubina, Chief Executive Officer, can be contacted via email at henry.dubina@telescopeinn.com.
Source: Telescope Innovations Corp.
